Table 2 Characteristics of 209 patients with JIA taking etanercept or infliximab as the first anti-TNF therapy
Total cohortEtanerceptInfliximabDifference* (p value)
n209105104
Gender male/female, n/n (%)64/145 (31/69)26/79 (25/75)38/66 (36/64)0.073
Type of JIA
    Persistent oligoarthritis, n (%)16 (7.6)1 (1.0)15 (14.3)0.001
    Extended oligoarthritis, n (%)42 (20.0)19 (18.1)23 (21.9)ns
    Seronegative polyarthritis, n (%)104 (50.0)62 (59.0)42 (40.0)0.013
    Seropositive polyarthritis, n (%)9 (4.3)4 (3.8)5 (4.8)ns
    Systemic JIA, n (%)13 (6.2)11 (10.5)2 (1.9)0.019
    Enthesitis-related arthritis, n (%)21 (10.0)8 (7.6)13 (12.4)ns
    Psoriatic arthritis, n (%)4 (1.9)04 (3.8)ns
ANA positive, n/n examined (%)88/205 (43)36/103 (35)52/102 (51)0.024
Uveitis, n (%)75 (36)30 (29)45 (43)0.031
HLA-B27 positive, n/n examined (%)70/184 (38)40/94 (43)30/90 (33)ns
Onset of JIA, mean (range) years5.1 (0.7–15.9)4.5 (2.2–15.9)5.6 (0.7–14.8)0.023
Age at initiation of BA, mean (range) years10.1 (2.2–15.9)9.6 (2.2–15.9)10.6 (4.0–15.9)0.074
Duration of JIA, mean (range) years5.0 (0.3–13.7)5.1 (0.3–13.7)4.9 (0.3–12.8)ns
No of DMARD at baseline, mean (range)2.1 (0–5)2.2 (0–5)1.9 (0–4)0.012
Prednisolone (mg/kg) at baseline,† mean (range)0.2 (0–3.8)0.2 (0–3.8)0.1 (0–1.7)0.014
  • *Between etanercept and infliximab treatment groups. †Prednisolone mg/kg alternate days. ANA, antinuclear antibody (titre ⩾1 : 160); BA, biological agents; DMARD, disease-modifying antirheumatic drug; HLA-B27, human leucocyte antigen B27; JIA, juvenile idiopathic arthritis; TNF, tumour necrosis factor.